Squamous cell carcinoma

Albert Einstein College of Medicine Researchers Develop Promising New Cancer Therapy

Retrieved on: 
Tuesday, November 15, 2022
Albert Einstein College of Medicine, Technology, NK, Immunotherapy, Immunity, Student, YouTube, Microbiology, College, Melanoma, Ageing, Squamous cell carcinoma, University Hospital (Newark, New Jersey), AIDS, Diabetes, National, Lung, Attention, Lymphoma, PVR, Stomach, Partnership, Myeloid leukemia, Liver disease, Patient, Degenerative disease, Protein, Pembrolizumab, Paper, Pancreatic cancer, College of Medicine, Doctor of Philosophy, Montefiore, Microdeletion syndrome, Journal, Urology, Teaching hospital, Journal of Clinical Investigation, Multimedia, College of Medicine (UK), Head, Neuroscience, Neoplasm, JCI, Neck, TIGIT, Acute myeloid leukemia, Research, Patent, Albert Einstein, Large-cell lung carcinoma, Cancer research, Pharmaceutical industry, Vaccine, Cancer, Medicine, Facebook

Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement.

Key Points: 
  • Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement.
  • In a paper published online today in The Journal of Clinical Investigation (JCI), scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy.
  • Rather than rally T cells against cancer, the Einstein research team used different human immune cells known as natural killer (NK) cellswith dramatic results.
  • About Albert Einstein College of Medicine Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation.

GO2 for Lung Cancer Honors Champions of the Lung Cancer Community at Simply the Best XVII Gala

Retrieved on: 
Monday, November 14, 2022
SAN, Doctor of Philosophy, Vanderbilt University Medical Center, Family, Lung cancer, ASCI, Squamous cell carcinoma, Health, Technology, MD, American Association, Work, Vanderbilt-Ingram Cancer Center, Friends, American Society for Clinical Investigation, American Association for Cancer Research, Physician, Survivor, Leadership, Bonnie J. Addario Lung Cancer Foundation, Best, Medicine, Caregiver, Hope, ASCO, Society, Editorial board, Research, Daiichi Sankyo, ADC, Multimedia, Patient, AACR, International Association, Division, CEO, Associate, Large-cell lung carcinoma, JCO, Disease, American Society of Clinical Oncology, Uranium, Pharmaceutical industry, Medical imaging

SAN CARLOS, Calif.andWASHINGTON, Nov. 14, 2022 /PRNewswire/ -- GO2 for Lung Cancer (GO2) honored leadership in lung cancer research and treatment, as well as dedicated caregiving, at its Simply the Best XVII Gala held in San Francisco on November 12.

Key Points: 
  • SAN CARLOS, Calif.andWASHINGTON, Nov. 14, 2022 /PRNewswire/ -- GO2 for Lung Cancer (GO2) honored leadership in lung cancer research and treatment, as well as dedicated caregiving, at its Simply the Best XVII Gala held in San Francisco on November 12.
  • Daiichi Sankyo was honored with this award for their commitment to advancing lung cancer oncology discovery to meet the needs of all patients.
  • "I'm so honored to be recognized by GO2 for Lung Cancer for my work to bring targeted, personalized and more effective treatments to lung cancer patients," said Dr. Lovly.
  • GO2 for Lung Cancer is leading the charge to confront lung cancer and we're taking it on relentlessly from every front, every day.

STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING

Retrieved on: 
Monday, November 14, 2022
Jazz Pharmaceuticals, MRCPCH, Doctor of Philosophy, PSA, KRAS, Tobacco Products Scientific Advisory Committee, Radon, FAC, SU2C, Entertainment Industry Foundation, Awareness, Partnership, Safety, Non-Smokers' Rights Association, Cancer, Research, Noreen Fraser Foundation, Smoking, Squamous cell carcinoma, Multimedia, Lung cancer, Patient, Small-cell carcinoma, Air pollution, CEO, Stand Up to Cancer, Large-cell lung carcinoma, Diagnosis, Radio, Young adult, Disease, Smoke, Pharmaceutical industry, Black, Adolescence

The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and encourage listeners to learn about screening options.

Key Points: 
  • The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer and encourage listeners to learn about screening options.
  • "Additionally, we are incredibly thankful to Jazz Pharmaceuticals for the company's support of SU2C's Catalystprogram, including research to investigate potential new treatments for non-small cell lung cancer."
  • "Jazz is committed to transforming the lives of patients and their families, and our collaboration with Stand Up To Cancer on this PSA campaign aims to spread awareness of small cell lung cancer and encourage early screening.
  • Stand Up To Cancer recently announced the funding of three SU2C Catalyst research projects with support from Jazz Pharmaceuticals.

EQS-News: CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Retrieved on: 
Friday, November 11, 2022
Degenerative disease, Adenoid cystic carcinoma, Melanoma, SITC, Society, CVAC, CureVac, Protein, RNA, European Society for Medical Oncology, Immunotherapy, GSK, Biopsy, Technology, PD-1, Cell, Oncology, Patient, Neck, Vaccine, Infection, Immune system, Safety, ESMO, Tumor microenvironment, Neoplasm, RNA transfection, COVID-19, Head, Nasdaq, Squamous cell carcinoma, B cell, RECIST, Pharmaceutical industry

TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.

Key Points: 
  • TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.
  • Preliminary results from the completed Phase 1 expansion study in patients with PD-1 refractory melanoma confirm a robust safety profile of CV8102 as a single agent and in combination with anti-PD-1 antibodies.
  • The data we collected in the heavily pretreated patients of our Phase 1 expansion study further confirm the safety and immuno-modulatory activity of CV8102, said Ulrike Gnad-Vogt, interim Chief Development Officer at CureVac.
  • The Phase 1, open-label, dose escalation and expansion study of CV8102 aims to assess safety, tolerability and efficacy of CV8102 as a single agent and in combination with licensed PD1-antibodies.

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, IND, U.S. Securities and Exchange Commission, HBV, Squamous cell carcinoma, Food, Nasdaq, Immunotherapy, Risk, Neoplasm, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Gram-negative bacteria, SEC, Annual report, Safety, Policy, Inflammation, Company, Toxicity, Immunology, Government, Clinical trial, Research, Liver, Patient, Immune system, Infection, Security (finance), Spleen, HIV, Toxicology, Pharmaceutical industry, Decoy

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update.

Key Points: 
  • NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (Indaptus or the Company), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update.
  • The study protocol allows for exploration of additional dosing regimens, including continuous weekly administration after initial safety has been established.
  • Decoy20 has the potential to treat a wide range of solid tumors including hepatocellular, colorectal and pancreatic carcinomas.
  • As of September 30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $28.5 million.

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, Bristol Myers Squibb, Nivolumab, AHR, TEAD, Toxic leukoencephalopathy, Tumor microenvironment, Annual general meeting, Immunotherapy, RAS, Dor, Bladder cancer, Society for Immunotherapy of Cancer, RECIST, SEC, HIV disease progression rates, Patient, Hippopotamus, Biomarker, Cancer, Disease, Program, DCR, Combination, Society, MD, SITC, Pharmaceutical industry, Squamous cell carcinoma

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented initial clinical data from its ongoing IK-175 clinical program in urothelial carcinoma at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.

Key Points: 
  • BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented initial clinical data from its ongoing IK-175 clinical program in urothelial carcinoma at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.
  • We are glad to share the initial results from this study showing encouraging antitumor activity of IK-175 in urothelial carcinoma.
  • These initial data suggest we are making progress towards demonstrating that IK-175 in combination with nivolumab could overcome resistance to immune checkpoint inhibitors in urothelial carcinoma.
  • Initial results demonstrate durable antitumor activity in heavily pretreated patients in both monotherapy and combination arms in urothelial carcinoma patients who all progressed on prior checkpoint inhibitors.

Jounce Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Investor, European Society for Medical Oncology, Partnership, ICOS, Immunotherapy, Research, Macrophage, Family, G&A, SELECT, Therapy, PD-L1, PD-1, Conference, Society for Immunotherapy of Cancer, ILT4, Security (finance), Review, LILRB4, Marketing, Tumor microenvironment, CCR8, Gilead Sciences, U.S. Securities and Exchange Commission, BTC, Pharmacokinetics, Private Securities Litigation Reform Act, Cancer, Patient, COVID-19, LILRB2, Webcast, Oncology, Neoplasm, HNSCC, Myelocyte, Public expenditure, Poster, Society, Congress, POC, GLOBE, PFS, Head, Intellectual property, Investment, ESMO, Cholangiocarcinoma, Annual report, NASDAQ, Safety, ILT3, Immune system, Heart, Squamous cell carcinoma, SITC, Life insurance, Pharmaceutical industry, Vaccine, IND, Fourth, fifth, and sixth derivatives of position

- Ended the quarter with $130.3 million in cash, cash equivalents and investments -

Key Points: 
  • - Ended the quarter with $130.3 million in cash, cash equivalents and investments -
    CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Third Quarter 2022 Financial Results:
    Cash position: As of September 30, 2022, cash, cash equivalents and investments decreased to $130.3 million, compared to $220.2 million as of December 31, 2021.
  • License and collaboration revenue: Jounce did not recognize any revenue during the third quarter of 2022 or 2021.
  • Based on its current operating and development plans and cost containment efforts, Jounce is reiterating its financial guidance for 2022.

RAPT Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Congress, U.S. Securities and Exchange Commission, Therapy, Risk, Oncology, Research, Large-cell lung carcinoma, Atopic dermatitis, RAPT, Squamous cell carcinoma, Safety, Asthma, Inflammation, Company, Cancer, CCR4, European Society for Medical Oncology, Patient, Neck, Security (finance), COVID-19, Pharmaceutical industry, Renewable energy

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter and nine months ended September 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter and nine months ended September 30, 2022.
  • Financial Results for the Third Quarter and Nine Months Ended September 30, 2022
    Third Quarter Ended September 30, 2022
    Net loss for the third quarter of 2022 was $21.2 million, compared to $18.7 million for the third quarter of 2021.
  • Research and development expenses for the third quarter of 2022 were $16.6 million, compared to $15.7 million for the same period in 2021.
  • General and administrative expenses for the third quarter of 2022 were $5.1 million, compared to $3.8 million for the same period in 2021.

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Squamous cell carcinoma, U.S. Securities and Exchange Commission, Forward-looking statement, Intellectual property, Congress, Investment, Amifampridine, ESG, Adult, Patent, Accounting, Tablet, New Drug Application, Depreciation, Health Canada, Index, COVID-19, Companies listed on the Toronto Stock Exchange (A), Kayleigh McEnany, Mission statement, SEC, Annual report, Share repurchase, Goal, LEMS, Achievement, Lambert–Eaton myasthenic syndrome, Catalyst Pharmaceuticals, Orange Book, Lesbian flag, Company, Conference call, United, Research, Conference, GAAP, Degenerative disease, Patient, Growth, CEO, Industry, Acquisition, FDA, Income, Beauty salon, Pharmaceutical industry, Renewable energy, Fine chemical, Video game, Online shopping, Catalysis, Webcast, Social

"Catalyst delivered another solid quarter driven by record net revenues that exceeded expectations, marking this as another strong quarter of sequential growth of our FIRDAPSE brand.

Key Points: 
  • "Catalyst delivered another solid quarter driven by record net revenues that exceeded expectations, marking this as another strong quarter of sequential growth of our FIRDAPSE brand.
  • With robust year-to-date performance and continued momentum going into the fourth quarter, we are raising our 2022 full year total revenue guidance to $205-210 million."
  • In the third quarter of 2022 we were ranked #39 in the 2022 Fortune 100 Fastest Growing Companies List.
  • Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Retrieved on: 
Wednesday, November 9, 2022
IND, Communication, Research, CNMV, Development, Sale, Person, NEC Laboratories America, Survival, Fox Chase Cancer Center, CRADA, Associate, Squamous cell carcinoma, Phase II, NETS, Forward-looking statement, Prevalence, Azacitidine, B cell, ISIN, FLT3, Prospectus, FCCC, Mercado, Cancer, Gastrointestinal tract, AML, Patient, MD, NCI, NET, Investigational New Drug, Cooperative research and development agreement, Hematological Cancer Research Investment and Education Act, Medulloblastoma, EHA, Acute myeloid leukemia, NEC, Mission statement, Public expenditure, Growth, FDA, GLOBE, Carcinoma, ORY, ESMO, Wilms' tumor, Spanish, Safety, LSD1, Genomics, ALICE, Prognosis, Pharmaceutical industry, SCLC, EU

Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.

Key Points: 
  • Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.
  • Response rates for NECs and SCLC in second line are generally less than 5% and 20%, respectively, and survival is measured in months.
  • There are very few treatment options for these patients and even fewer trials, which makes this effort even more important.
  • In total iadademstat has been dosed so far to more than 100 cancer patients in four clinical trials.